Economic Influence on the Development of New Pharmaceuticals
NOV 29, 2016 | CONTAGION EDITORIAL STAFF
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, discusses the economic opportunities driving the development of new pharmaceuticals.
Interview Transcript (slightly modified for readability)
“Certainly the discovery of new antimicrobial targets is different; however, a majority of what’s happening in the industry is really being driven by economic reasons. For example, there’s [been] $360 billion of pharmaceuticals purchased in the US in 2014; [whereas] just in the hospital setting alone, where resistance is the greatest, there’s only $1.9 billion being spent.
When you compare the $360 billion overall with the $1.9 billion in the hospital setting, there is a clear shift towards therapies other than those antibiotics used in the hospital setting. If you look at the amount of money spent on any pharmaceutical, there was $6.5 billion spent in 2014 on a hepatitis C drug, but if you look at the two antibiotics for gram-negative infections that were approved, in the first 12 months [they] gathered $10 [million] to $20 million in annual sales.
Again, when you look at the amount of sales [for] an antibiotic in the inpatient [setting], versus a drug for hepatitis C, you can see a huge difference between the $6.5 billion opportunity and the $10 [million] to $20 million opportunity.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512